Conferences
ESMO 2017: Immune Checkpoint Inhibitors in Prostate Cancer
September 11, 2017
ESMO 2017: Comparison of tumor mutational burden in relevant molecular subsets of metastatic urothelial cancer
September 11, 2017
ESMO 2017: Therapeutic Vaccines in Prostate Cancer
September 11, 2017
ESMO 2017: Adjuvant sunitinib in patients with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial
September 11, 2017
ESMO 2017: Immunogenomics of Lethal Prostate Cancer
September 11, 2017
ESMO 2017: Basic immunobiology in Prostate Cancer
September 11, 2017
ESMO 2017: Adding abiraterone for patients with high-risk prostate cancer (PCa) starting long-term ADT: Outcomes in non-metastatic (M0) patients from STAMPEDE
September 11, 2017
ESMO 2017: What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis
September 11, 2017
ESMO 2017: Phase Ib/II Trial of Interleukin-2 and Nivolumab in Metastatic Clear Cell Renal Cell Cancer
September 11, 2017
ESMO 2017: KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma
September 11, 2017
ESMO 2017: Will RANGE study impact the standard of care in metastatic urothelial carcinoma?
September 11, 2017